Kalypsys is focused on three therapeutic areas that target some of the world's most widespread diseases including cardiovascular/metabolic diseases, pain/inflammation and oncology. In each of these categories, we are working diligently to discover and develop innovative medicines which will help care for and cure patients suffering from these conditions. In 2006 we successfully filed two Investigational New Drug (IND) applications, and our plan to file additional IND's in 2007 reflects our aggressive approach to development.
Pharmaceutical companies are continually challenged in the drug discovery and development process by lengthy R&D; periods and high attrition rates. Kalypsys directly addresses these challenges with our integrated drug discovery infrastructure.
This unique, proprietary infrastructure increases efficiency and speeds productivity in several ways. The Kalypsys technology platform is unparalleled in its ability to rapidly identify and select the best leads with superior drug-like profiles for medicinal chemistry and preclinical development. Our commitment to translational medicine improves quality and reduces attrition by providing an early understanding of a drug candidate's properties prior to moving into full clinical development. Our seamless discovery and development allows Kalypsys to substantially reduce time and cost.
In addition to the development of our own pipeline, we partner with top-tier pharmaceutical companies to rapidly advance their next generation of medicines.
Corporate Fact Sheet (140 KB)Corporate Fact Sheet - Print Version (2 MB)